[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Franz B. Humer, Director at Allogene Therapeutics (ALLO), received a grant of 95,400 Restricted Stock Units (RSUs) on June 18, 2025. The RSUs represent the right to receive an equivalent number of common stock shares.

Key terms of the RSU grant:

• Vesting Schedule: Equal semi-annual installments over one year from grant date
• Exercise Price: $0
• Special Deferral: Humer elected to defer receipt of shares until either:
• 30 days after Board separation, or
• Company change in control

This Form 4 filing was submitted by Earl Douglas (Attorney-in-fact) on June 20, 2025, reporting the transaction under Section 16(a) of the Securities Exchange Act. The grant appears to be part of the company's Non-Employee Director Compensation Policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humer Franz B

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/18/2025		A		95,400		(1)	(1)	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Remarks:

	Earl Douglas, Attorney-in-fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did Franz Humer receive from ALLO on June 18, 2025?

Franz Humer received 95,400 Restricted Stock Units (RSUs) from Allogene Therapeutics (ALLO) on June 18, 2025. Each RSU represents a contingent right to receive one share of the Company's Common Stock.

What is the vesting schedule for ALLO director Franz Humer's RSU grant?

The RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to continued service on the board. The vesting schedule is structured as 47,700 RSUs vesting every six months.

When will Franz Humer receive the ALLO common stock from his RSU grant?

Humer has elected to defer receiving the common stock until the earlier of: (1) 30 days following his separation from ALLO's Board of Directors, or (2) a change in control of the Company, in accordance with ALLO's Non-Employee Director Compensation Policy.

What was the purchase price of the RSUs granted to ALLO director Franz Humer?

The RSUs were granted to Franz Humer at a price of $0, as indicated in the Form 4 filing under the 'Price of Derivative Security' column.